HIV Post-Exposure Prophylaxis Regimen
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV prevention methods, such as daily oral pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), face challenges with adherence and require prolonged administration, leading to inefficiencies and adverse reactions, necessitating a more effective and simplified regimen for immediate protection after exposure.
Innovation Solution
A combination of emtricitabine (FTC), tenofovir alafenamide (TAF), elvitegravir (EVG), and cobicistat (COBI) is administered in one or two oral doses after potential HIV exposure, providing post-exposure prophylaxis without the need for daily dosing or prolonged administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prolonged post-exposure prophylaxis (28 days) is administered, then HIV infection prevention effectiveness is improved, but treatment complexity and adverse drug reactions increase
Solution Approach 1:
The patent applies preliminary action by administering a high dose of antiretroviral medication immediately after potential HIV exposure to establish protective levels before the virus can establish infection. This single or two-dose preliminary intervention replaces the need for prolonged 28-day treatment, achieving prevention effectiveness while reducing treatment complexity and duration.
2Reliability
If daily oral pre-exposure prophylaxis is administered, then HIV infection prevention effectiveness is improved, but adherence requirements and treatment duration increase
Solution Approach 1:
The patent applies periodic action by replacing continuous daily dosing with intermittent high-dose administration only when needed - specifically, one or two doses given within hours to days after potential exposure. This periodic intervention maintains prevention effectiveness while dramatically reducing adherence burden from daily to occasional dosing.
3Reliability
If prolonged antiretroviral therapy is administered, then HIV transmission reduction is improved, but cost and clinical management requirements increase
Solution Approach 1:
The patent applies taking out by extracting the essential preventive function from prolonged continuous therapy and concentrating it into a single or two-dose post-exposure intervention. This extracts the core transmission prevention capability while removing the burden of prolonged clinical management, monitoring, and adherence support required for 28-day regimens.
Data Source
Figure 1
AI summary
Disclosed is the use of a nucleoside reverse transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, and an integrase inhibitor after exposure to a potential human immunodeficiency virus (HIV) infection to inhibit or prevent an HIV infection. In some embodiments, a pharmacologically effective amount of emtricitabine (FTC), a pharmacologically effective amount of tenofovir alafenamide (TAF) or tenofovir disproxil fumarate (TDF), a pharmacologically effective amount of the integrase inhibitor elvitegravir (EVG), and optionally cobistat (COBI) are used to inhibit or prevent an HIV infection, wherein these agents are administered only after a potential exposure to HIV. In specific non-limiting examples, only one or two doses of the anti-retroviral viral agents are administered to a subject after the potential exposure to HIV.